期刊文献+
共找到51篇文章
< 1 2 3 >
每页显示 20 50 100
Design,delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo 被引量:9
1
作者 Wolfgang H.Caselmann Matthias Serwe +3 位作者 Thomas Lehmann János Ludwig Brian S.Sproat Joachim W.Engels 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第5期626-629,共4页
Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be ... Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be treated effectively.Toimprove this response rate we used antisensetechnologies to inhibit HCV translation as possibleadditional option for experimental treatment.Antisense oligodeoxynucleotides(ODN) are 展开更多
关键词 hepatitis C-like viruses/therapy gene expression in VITRO in vivo nucleic acids/therapeutic use CYTOMEGALOVIRUS
下载PDF
Therapeutic and Medicinal Uses of <i>Aloe vera</i>: A Review 被引量:5
2
作者 Pankaj K. Sahu Deen Dayal Giri +5 位作者 Ritu Singh Priyanka Pandey Sharmistha Gupta Atul Kumar Shrivastava Ajay Kumar Kapil Dev Pandey 《Pharmacology & Pharmacy》 2013年第8期599-610,共12页
The plant Aloe vera is used in Ayurvedic, Homoeopathic and Allopathic streams of medicine, and not only tribal community but also most of the people for food and medicine. The plant leaves contains numerous vitamins, ... The plant Aloe vera is used in Ayurvedic, Homoeopathic and Allopathic streams of medicine, and not only tribal community but also most of the people for food and medicine. The plant leaves contains numerous vitamins, minerals, enzymes, amino acids, natural sugars and other bioactive compounds with emollient, purgative, anti-microbial, anti inflammatory, antioxidant, aphrodisiac, anti-helmenthic, antifungal, antiseptic and cosmetic values for health care. This plant has potential to cure sunburns, burns and minor cuts, and even skin cancer. The external use in cosmetic primarily acts as skin healer and prevents injury of epithelial tissues, cures acne and gives a youthful glow to skin, also acts as extremely powerful laxative. 展开更多
关键词 ALOE vera Antimicrobial therapeutic MEDICINAL useS Cosmetic Application
下载PDF
Blastocystis hominis as a cause of chronic diarrhea in low-resource settings:A systematic review
3
作者 Stephen Amoak Jonathan Soldera 《World Journal of Meta-Analysis》 2024年第3期30-41,共12页
BACKGROUND Blastocystis hominis(B.hominis),an anaerobic unicellular protist parasite,is known for its diverse clinical manifestations upon infecting the human gastrointestinal tract.Although globally distributed,it is... BACKGROUND Blastocystis hominis(B.hominis),an anaerobic unicellular protist parasite,is known for its diverse clinical manifestations upon infecting the human gastrointestinal tract.Although globally distributed,it is particularly prevalent in developing nations.Examining the symptoms and treatment outcomes of B.hominis infection in low-resource settings holds immense significance,providing healthcare practi-tioners with valuable insights to enhance patient care.AIM To synthesize existing evidence on the symptomatology and treatment outcomes of B.hominis infection in low-resource settings.METHODS Following the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines,a systematic review was conducted.The search spanned electronic databases including PubMed,Scopus,and Google Scholar.After a comprehensive screening process,a thorough examination of the papers,adhering to inclusion and exclusion criteria,and data extraction from eligible studies was conducted.The findings underwent summarization through simple descriptive analysis.RESULTS The search yielded 1200 papers,with 17 meeting inclusion criteria.Chronic diarrhea due to B.hominis infection was reported in only two studies,while abdominal pain,diarrhea,flatulence,constipation,and nausea/vomiting emerged as the most commonly documented symptoms.Recovery rates after one week of treatment ranged from 71.8%to 100%,and after two weeks,from 60%to 100%.CONCLUSION In low-resource settings,chronic diarrhea resulting from B.hominis infection is infrequent.Common symptoms include abdominal pain,diarrhea,flatulence,constipation,and nausea/vomiting.Post-treatment,clinical outcomes are notably favorable,supporting the recommendation for treatment.Metronidazole is advocated as the first-line agent,with consideration for switching to a second-line option in cases of treatment failure or poor response. 展开更多
关键词 Blastocystis infections Gastrointestinal diseases Treatment outcome Developing countries Metronidazole/therapeutic use
下载PDF
Continuous Wear of Hydrogel Contact Lenses for Therapeutic Use
4
作者 Daisuke Kudo Hiroshi Toshida +1 位作者 Toshihiko Ohta Akira Murakami 《Open Journal of Ophthalmology》 2012年第4期110-113,共4页
Purpose: To investigate the efficacy and complications of continuous wear of etafilcon A for therapeutic use. Materials and Methods: The subjects were 228 eyes of 219 outpatients prescribed contact lens (CL) for one w... Purpose: To investigate the efficacy and complications of continuous wear of etafilcon A for therapeutic use. Materials and Methods: The subjects were 228 eyes of 219 outpatients prescribed contact lens (CL) for one week of continuous therapeutic wear during 10 years. The reason for prescription of CLs, the primary disease, the duration of CL wear and the complications were assessed retrospectively. Results: The predominant reason for prescription of CLs was relief of pain or a foreign-body sensation (62.3%) and protection of the corneal epithelium (20.6%). The primary disease was post-penetrating keratoplasty (36.8%), followed by corneal epithelial erosion (14.5%), post-lamellar keratoplasty (14.0%) and bullous keratopathy (12.2%). The average duration of wearing single lens was 6.5 ± 3.2 days. The average duration of wearing CLs in total was 9.2 ± 10.7 months. The most frequent problem associated with continuous wear of CLs was their dropping out of CLs (12.3%). The complications associated with CLs included conjunctivitis with papillary hyperplasia, corneal erosion and superficial punctate keratitis, but corneal ulcer and corneal infiltrates were not found. Conclusion: Serious complications were not shown changing the lenses every week to keep to the prescribed time limit for continuous therapeutic wear, even if corneal epithelial barrier function is impaired. 展开更多
关键词 therapeutic use BANDAGE Soft Contact LENS CONTINUOUS WEAR COMPLICATION
下载PDF
Comparison of long-lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration 被引量:3
5
作者 REN Ming Shan, ZHANG Zhi, WU Jun Xia, LI Fei, XUE Ben Chun and YANG Ren Min 《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第6期75-77,共3页
AIM To compare the long term effect of succimer (Suc) with that of penicillamine (Pen) in treating hepatolenticular degeneration (HLD). METHODS One hundred and twenty patients with HLD were divided into 2 groups. ... AIM To compare the long term effect of succimer (Suc) with that of penicillamine (Pen) in treating hepatolenticular degeneration (HLD). METHODS One hundred and twenty patients with HLD were divided into 2 groups. Group A ( n =60) received Suc 750mg , po. bid. Group B ( n =60) received Pen 250mg , po. qid. The period of maintenance treatment varied from 6 months to 3 years, averaging 1 5 years. Symptoms and therapeutic effects were evaluated by modified Goldstein scale. RESULTS The total effectiveness of group A in two different periods of treatment were 80% and 85% respectively, higher than those of group B (58% and 59% respectively) ( P <0 05). Suc also had obvious curative effects for the patients who failed in the use of Pen. There were fewer side effect in group A than in group B ( P <0 05). Suc and Pen could increase urinary copper excretion effectively and continually. CONCLUSION Suc is more effective and safer than Pen. Clinically, it can replace Pen as first choice drug for long term maintenance therapy of HLD. 展开更多
关键词 hepatolenticular degeneration/drug THERAPY succimer/therapeutic use penicillamine/therapeutic use
下载PDF
Functional dyspepsia of ulcer-dysmotility type:clinical incidence and therapeutic strategy 被引量:3
6
作者 WANG XiaoZhong and LIN GuZhen 《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第4期95-96,共2页
Functionaldyspepsiaofulcerdysmotilitytype:clinicalincidenceandtherapeuticstrategyWANGXiaoZhongandLINGuZhe... Functionaldyspepsiaofulcerdysmotilitytype:clinicalincidenceandtherapeuticstrategyWANGXiaoZhongandLINGuZhenSubjectheaadings... 展开更多
关键词 dyspepsia/drug therapy famotidine/therapeutic use cisapride/therapeutic use peptic ULCER gastrointestinal motility
下载PDF
Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract 被引量:5
7
作者 Tsunenori Kondo Toshio Takagi Kazunari Tanabe 《World Journal of Clinical Oncology》 CAS 2015年第6期237-251,共15页
Lymphadenectomy for urothelial carcinoma of the upper urinary tract has attracted the attention of physicians. The mapping study of lymphatic spread has shown that a relatively wide area should comprise the regional n... Lymphadenectomy for urothelial carcinoma of the upper urinary tract has attracted the attention of physicians. The mapping study of lymphatic spread has shown that a relatively wide area should comprise the regional nodes for tumors of the right renal pelvis or the right upper two-thirds of the ureter. A prospective study showed that an anatomical templatebased lymphadenectomy significantly improved patient survival in tumors of the renal pelvis. This benefit was more evident for patients with p T2 stage tumors or higher. The risk of regional node recurrence is significant reduced by template-based lymphadenectomy,which is likely to be associated with improved patient survival. The removal of lymph node micrometastases is assumed to be the reason for therapeutic benefit following lymphadenectomy. The number of resected lymph nodes can be used to assess the quality of lymphadenectomy,but not to determine the extent of lymphadenectomy. The guidelines currently recommend lymphadenectomy for patients with muscle-invasive disease,even though the current recommendation grades are still low. The present limitation of lymphadenectomy is the lack of standardization of the extent of lymphadenectomy and the randomized trials. Further studies are warranted to collect the evidence to support lymphadenectomy. 展开更多
关键词 LYMPHADENECTOMY LYMPH node EXCISION UROTHELIAL carcinoma Treatment outcome therapeutic uses Diagnosis GUIDELINE
下载PDF
Controversies regarding transplantation of mesenchymal stem cells
8
作者 Tsvetelina Velikova Tereza Dekova Dimitrina Georgieva Miteva 《World Journal of Transplantation》 2024年第2期48-61,共14页
Mesenchymal stem cells(MSCs)have tantalized regenerative medicine with their therapeutic potential,yet a cloud of controversies looms over their clinical tran-splantation.This comprehensive review navigates the intric... Mesenchymal stem cells(MSCs)have tantalized regenerative medicine with their therapeutic potential,yet a cloud of controversies looms over their clinical tran-splantation.This comprehensive review navigates the intricate landscape of MSC controversies,drawing upon 15 years of clinical experience and research.We delve into the fundamental properties of MSCs,exploring their unique immuno-modulatory capabilities and surface markers.The heart of our inquiry lies in the controversial applications of MSC transplantation,including the perennial debate between autologous and allogeneic sources,concerns about efficacy,and lingering safety apprehensions.Moreover,we unravel the enigmatic mechanisms surro-unding MSC transplantation,such as homing,integration,and the delicate balance between differentiation and paracrine effects.We also assess the current status of clinical trials and the ever-evolving regulatory landscape.As we peer into the future,we examine emerging trends,envisioning personalized medicine and innovative delivery methods.Our review provides a balanced and informed perspective on the controversies,offering readers a clear understanding of the complexities,challenges,and potential solutions in MSC transplantation. 展开更多
关键词 Mesenchymal stem cells Transplantation controversies Regenerative medicine Autoimmune diseases Chronic inflammatory illnesses Tumor growth METASTASIS therapeutic potential Clinical use of mesenchymal stem cell
下载PDF
Clinacanthus nutans:a review of the medicinal uses,pharmacology and phytochemistry 被引量:10
9
作者 Md.Ariful Alam Sahena Ferdosh +4 位作者 Kashif Ghafoor Md.Abdul Hakim Abdul Shukor Juraimi Alfi Khatib Md.Zaidul I.Sarker 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第4期393-399,共7页
Clinacanthus nutans Lindau is known as snake grass belonging to the Acanlhaceae family.This plant has diverse and potential medicinal uses in traditional herbal medicine for treating skin rashes,insects and snake bite... Clinacanthus nutans Lindau is known as snake grass belonging to the Acanlhaceae family.This plant has diverse and potential medicinal uses in traditional herbal medicine for treating skin rashes,insects and snake bites,lesions caused by herpes simplex virus,diabetes,and gout in Malaysia.Indonesia.Thailand and China.Phylochemieal investigations documented the varied contents of bioaclive compounds from litis plant namely flavonoids,glycosides,glycoglyeerolipids.cerebrosides and monoacylmonogalatosylglycerol.The pharmacological experiment proved that various types of extracts and pure compounds from this species exhibited a broad range of biological properties such as anti-inflammatory,antiviral,antioxidant,and anti-diabetic activities.The lindings of toxicity study showed that extracts from this plant did not show any toxicity thus it can be used as strong therapeutic agents for specific diseased conditions.However,further experiments on chemical components and their mode of action showing biological activities are required to elucidate the complete phytochemical profile and assess to confirm their suitability tor future drugs.This review summarizes the medicinal uses,phytochemistry and pharmacology of this plant in order to explore its therapeutic potential and gaps necessitating for prospected research work. 展开更多
关键词 Clinacanthus nutans MEDICINAL useS PHYTOCHEMICALS PHARMACOLOGY therapeutic potential
下载PDF
High-intensity focused ultrasound extracorporeal ablation of liver tissuesin rabbits
10
《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第2期16-16,共1页
HighintensityfocusedultrasoundextracorporealablationoflivertissuesinrabbitsCHENGShuQun1,ZHOUXinDa1,TANGZ... HighintensityfocusedultrasoundextracorporealablationoflivertissuesinrabbitsCHENGShuQun1,ZHOUXinDa1,TANGZhaoYou1,YUYao1,B... 展开更多
关键词 LIVER neoplasms experimental/therapy ultrasonic THERAPY iodized oil/therapeutic use liver/radiation effects randomized controlled trials
下载PDF
The role of drug utilization evaluation in medical sciences
11
作者 Ruby Gangwar Arvind Kumar +2 位作者 Abrar Ahmed Zargar Amit Sharma Ranjeet Kumar 《Global Health Journal》 2023年第1期3-8,共6页
Background:Drug utilization evaluation(DUE)is defined by the World Health Organization(WHO)and focuses on the medical,social,and economic consequences of pharmaceutical marketing,distribution,prescribing,and usage in ... Background:Drug utilization evaluation(DUE)is defined by the World Health Organization(WHO)and focuses on the medical,social,and economic consequences of pharmaceutical marketing,distribution,prescribing,and usage in society.The WHO recommends a physician to every 1000 people.According to the recent data from the Health Ministry in 2019,in which 1.16 million doctors are of active population with just 80%,or 0.9 million,practicing.As a result,a ratio of 0.68 doctors for every 1000 people,which is much below as per the WHO reports.This article describes history,types,WHO guidelines,need and purpose of DUE.Objective:The main aim of this paper is to provide information about the rational use of medication in outpa­tient and inpatient department with special emphasis of DUEs.It also provides awareness directly to healthcare professionals,researchers,academicians,pharmacist and nurses to reduce the irrationality of medicines.Methods:The method used to compile this review information gathered from websites,Google scholar,PubMed,Research gate,and studies published on DUE from July 20 to Oct 22 were included as source of information.Results:We studied more than 35 published study on DUE,that reveals most of the physicians prescribed branded drugs not generic drugs,but WHO prescribing indicator allows to prescribe generic drugs in the hospital pharmacy to maintain better inventory control.It may also help to prevent pharmacist misunderstanding during dispensing.Conclusion:The use of generic prescription names avoids the possibility of medication product duplication and lowers patient costs.It is important to remember that incorrect medication prescriptions have impact on both patients and their family members.WHO indicators identify irrational prescribing behaviours to make therapy more rational and cost-effective. 展开更多
关键词 Anatomical therapeutic chemical classification Drug utilization evaluation Prescribing indicators Pregnancy risk classification Rational use of the drug
下载PDF
USE OF CELL-BASED BIOASSAY FOR THE QUALITY CONTROL OF BOTANICAL THERAPEUTICS
12
作者 Doo Suk Lee Min-Jung Bae Sunyoung Kim 《World Journal of Traditional Chinese Medicine》 2015年第4期91-91,共1页
The single most important factor in modernization efforts of traditional oriental medicines is the limited understanding of active compounds responsible for claimed therapeutic effects.Indeed,the unknown identity of b... The single most important factor in modernization efforts of traditional oriental medicines is the limited understanding of active compounds responsible for claimed therapeutic effects.Indeed,the unknown identity of biologically active molecules generates major difficulties associated with botanical therapeutics in general.This includes management of raw materials,poor understanding of 展开更多
关键词 use OF CELL-BASED BIOASSAY FOR THE QUALITY CONTROL OF BOTANICAL therapeuticS PG
原文传递
联合应用雷替曲塞及表柔比星经肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察 被引量:28
13
作者 王保信 武振明 +6 位作者 张锐 胡新华 邹庆华 范宜锋 邢宏建 肖芳芳 齐秀恒 《临床肝胆病杂志》 CAS 2015年第5期725-728,共4页
目的:评价雷替曲塞联合表柔比星介入肝动脉灌注化疗栓塞在治疗中晚期原发性肝癌中的疗效。方法选取中国石油天然气集团公司中心医院2011年1月-2013年5月收治的80例不适合手术治疗的中晚期原发性肝癌患者,将其随机分为研究组和对照组... 目的:评价雷替曲塞联合表柔比星介入肝动脉灌注化疗栓塞在治疗中晚期原发性肝癌中的疗效。方法选取中国石油天然气集团公司中心医院2011年1月-2013年5月收治的80例不适合手术治疗的中晚期原发性肝癌患者,将其随机分为研究组和对照组,每组40例。研究组给予雷替曲塞联合表柔比星介入下肝动脉灌注化疗栓塞治疗,对照组给予氟尿嘧啶(5-FU)联合表柔比星介入下肝动脉灌注化疗栓塞治疗。以上治疗每4周1次,共进行3~6周期。观察两组的治疗有效率(RR)、疾病控制率(DCR)、中位疾病进展时间、生存率以及甲胎蛋白(AFP)、癌胚抗原(CEA)、转氨酶、胆红素的下降情况。计数资料组间比较采用χ2检验,计量资料组间比较采用 t 检验。结果研究组的 RR 为52.5%,对照组为22.5%,差异均有统计学意义(χ2=7.680,P =0.006);研究组的 DCR 为87.5%,对照组为60.0%,差异有统计学意义(χ2=7.813,P =0.005);研究组的中位疾病进展时间为12.2个月,对照组为8.0个月,差异有统计学意义(t =5.118,P =0.00);研究组的1、2年生存率分别为为85.0%、60.0%,对照组分别为65.0%、37.5%,差异均有统计学意义(χ2值分别为4.267、4.053,P 值分别为0.039、0.044);研究组化疗栓塞术后1个月 AFP、转氨酶、胆红素水平下降超过50%的病例数均多于对照组,差异均具有统计学意义(χ2值分别为4.381、4.114、5.000,P 值分别为0.036、0.043、0.025)。结论雷替曲塞联合表柔比星介入肝动脉灌注化疗栓塞对治疗中晚期原发性肝癌有一定价值,值得在临床中推广。 展开更多
关键词 肝肿瘤 化学栓塞 治疗性 雷替曲塞 表柔比星
下载PDF
硼替佐米联合表柔比星及地塞米松方案治疗多发性骨髓瘤临床观察 被引量:6
14
作者 朱晶晶 李黎 +2 位作者 叶琇锦 何静松 蔡真 《实用肿瘤杂志》 CAS 2013年第5期520-523,共4页
目的观察硼替佐米联合表柔比星及地塞米松(PAD方案)治疗多发性骨髓瘤(multiple myeloma,MM)的疗效和安全性。方法共有103例MM患者接受过2~10个疗程PAD方案化疗。PAD方案:硼替佐米(万珂)1.0~1.3 mg/m2,在第1、4、8天和l1天给药,在3秒... 目的观察硼替佐米联合表柔比星及地塞米松(PAD方案)治疗多发性骨髓瘤(multiple myeloma,MM)的疗效和安全性。方法共有103例MM患者接受过2~10个疗程PAD方案化疗。PAD方案:硼替佐米(万珂)1.0~1.3 mg/m2,在第1、4、8天和l1天给药,在3秒内快速静脉注射;表柔比星9 mg/m2,在第2、5、9天和l2天给药;每次静脉注射硼替佐米当天及次日即第1、2、4、5、8、9、11天和12天,给予地塞米松20 mg加入0.9%生理盐水250 mL中静脉滴注,每28天为1个疗程。观察疗效和不良反应。结果总体反应率[完全缓解(CR)+接近完全缓解(nCR)+部分缓解(PR)+轻微反应(MR)]为88.3%(91/103),治疗有效率(CR+PR)为73.8%(76/103)。其中有32例在PAD方案治疗前接受过PD方案治疗的患者,23例有效,治疗有效率(CR+PR)为71.9%(23/32)。最常见的血液系统不良反应包括白细胞减少、贫血、血小板减少。非血液学不良反应主要为乏力、外周神经病变、腹泻/便秘等消化道症状、带状疱疹、呼吸道感染、浆膜腔积液/浮肿、血栓形成、皮疹、溶血等,经对症处理或延长化疗间歇时间后均可以减轻或恢复。结论 PAD方案在初发或难治复发的多发性骨髓瘤中均有较好的疗效,同时具有良好的安全性和耐受性。优于单药万珂或PD两药联合,可作为多发性骨髓瘤治疗的首选。 展开更多
关键词 多发性骨髓瘤 药物疗法 硼替佐米 治疗应用 表柔比星 治疗应用 地塞米松 治疗应用 治疗结果
下载PDF
不同制剂紫杉醇联合表柔比星治疗晚期乳腺癌的临床观察 被引量:17
15
作者 涂俊 杨娟 +1 位作者 刘景丽 瞿广桥 《实用肿瘤杂志》 CAS 2017年第2期168-172,共5页
目的探讨紫杉醇或白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效及不良反应。方法选取62例晚期乳腺癌患者,按照随机对照双盲的原则将其分为治疗组和对照组各31例,其中治疗组采用白蛋白结合型紫杉醇(260 mg/m^2)联合表柔比星(... 目的探讨紫杉醇或白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效及不良反应。方法选取62例晚期乳腺癌患者,按照随机对照双盲的原则将其分为治疗组和对照组各31例,其中治疗组采用白蛋白结合型紫杉醇(260 mg/m^2)联合表柔比星(75 mg/m^2)治疗,对照组采用紫杉醇(175 mg/m^2)联合表柔比星(75mg/m^2)治疗。治疗2个周期后,观察比较两组患者的临床疗效及不良反应发生情况。结果治疗组的治疗总有效率93.5%(29/31)高于对照组的71.0%(22/31),差异具有统计学意义(χ~2=5.420,P=0.020)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论与紫杉醇联合多柔比星比较,白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌疗效好且不良反应可耐受。 展开更多
关键词 乳腺肿瘤/药物疗法 表柔比星/投药和剂量 表柔比星/治疗应用 药物疗法 联合 紫杉酚/投药和剂量 紫杉酚/类似物和衍生物 血清白蛋白 双盲法 治疗结果
下载PDF
肝动脉灌注化疗及栓塞术中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效分析 被引量:8
16
作者 廖学斌 黄梦君 贺长林 《安徽医药》 CAS 2016年第5期972-975,共4页
目的比较肝动脉灌注化疗及栓塞术(TACE)中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效。方法选取行TACE治疗的不可切除肝癌患者100例,根据化疗方案不同分为伊立替康组(n=35)与表阿霉素组(n=65)。比较近期治疗效果、无进展生存期与总... 目的比较肝动脉灌注化疗及栓塞术(TACE)中运用伊立替康与表阿霉素治疗不可切除肝癌的疗效。方法选取行TACE治疗的不可切除肝癌患者100例,根据化疗方案不同分为伊立替康组(n=35)与表阿霉素组(n=65)。比较近期治疗效果、无进展生存期与总生存期、TACE后不良反应。结果两组患者近期疗效及TACE后不良反应比较差异无统计学意义(P>0.05)。伊立替康组中位无进展生存期为11.2个月,长于表阿霉素组(9.3个月),但差异无统计学意义(P>0.05);伊立替康组BCLC分级B亚组无进展生存期长于表阿霉素组(P<0.05)。伊立替康组患者1、2年生存率分别为85.7%、45.7%,均高于表阿霉素组(66.2%,21.5%)。伊立替康组及BCLC分级B亚组患者总生存期均长于表阿霉素组(P<0.05)。结论与表阿霉素传统化疗方案相比,TACE中运用伊立替康可延长不可切除肝癌患者的总生存期,且不良反应无差异。 展开更多
关键词 肝肿瘤 表柔比星 化学疗法 肿瘤 局部灌注 化学栓塞 治疗性 治疗结果 伊立替康
下载PDF
含表阿霉素的化疗方案治疗晚期乳腺癌28例分析 被引量:3
17
作者 张爱莲 李丽庆 《中国癌症杂志》 CAS CSCD 1999年第1期40-42,共3页
目的评估表阿霉素对晚期乳腺癌的临床疗效及安全性。方法随机采用50mg/m2、100mg/m2和135mg/m2三个剂量级联合方案治疗28例晚期乳腺癌患者。结果CR5例、PR13例,有效率64%;50mg/m2组9例,... 目的评估表阿霉素对晚期乳腺癌的临床疗效及安全性。方法随机采用50mg/m2、100mg/m2和135mg/m2三个剂量级联合方案治疗28例晚期乳腺癌患者。结果CR5例、PR13例,有效率64%;50mg/m2组9例,PR3例,100mg/m2组13例,CR4例,PR6例;135mg/m2组6例,CR1例,PR4例;随表阿素剂量增大有效率分别为33%、77%和83%。不良反应主要是白细胞减少,随剂量强度增大而增高,50mg/m2组,Ⅰ度22%;100mg/m2组Ⅰ、Ⅱ、Ⅲ、Ⅳ度分别为154%、30%、154%、76%,总发生率69%。135mg/m2组Ⅰ、Ⅱ、Ⅲ度分别为16%、50%和33%,占100%。肝、肾及心脏毒性轻微。结论高剂量EPI用于晚期乳腺癌治疗,剂量强度与治疗效果呈正相关,但骨髓抑制亦随之增高,若以GCSF支持,可望取得更好量效关系。 展开更多
关键词 晚期 乳腺癌 表阿霉素 药物疗法
下载PDF
含草酸铂方案治疗晚期胃癌近期疗效分析——附18例报告 被引量:32
18
作者 杨锡贵 宋恕平 +5 位作者 陈阵 周登光 牛作兴 郭珺 盛立军 刘波 《肿瘤防治杂志》 2002年第1期76-78,共3页
目的 :观察甲酰四氢叶酸钙 (CF)与 5 氟脲嘧啶 (5 FU)合用草酸铂 (OXA)和表阿霉素 (EPI)作为一线方案治疗晚期胃癌的疗效和毒性。方法 :共收治Ⅳ期胃癌 18例 ,其中低分化腺癌 10例 ,中分化腺癌 3例 ,黏液腺癌 3例 ,印戒细胞癌 2例。初... 目的 :观察甲酰四氢叶酸钙 (CF)与 5 氟脲嘧啶 (5 FU)合用草酸铂 (OXA)和表阿霉素 (EPI)作为一线方案治疗晚期胃癌的疗效和毒性。方法 :共收治Ⅳ期胃癌 18例 ,其中低分化腺癌 10例 ,中分化腺癌 3例 ,黏液腺癌 3例 ,印戒细胞癌 2例。初治 15例 ,复治 3例。方案包括CF 15 0mg m2 静脉滴入 2h ,第 1~ 5天 ,5 FU 375mg m2 持续静脉滴入 ,连续 12 0h ;国产草酸铂 80~ 10 0mg m2 静脉滴入 2h ,第 1天 ;EPI 60mg m2 静脉推注 ,第 1天 ;3~ 4周为 1个周期。结果 :CR 1例 ,PR 10例 ,NC 5例和PD 2例 ,总有效率 (CR +PR)为 61 1% (11 18)。中位缓解期 8个月 ,中位生存期 11个月 ,1年生存率为4 5 %。主要毒副反应为骨髓抑制和脱发。骨髓抑制为剂量限制性毒性 ,其中Ⅲ~Ⅳ度占 2 2 2 % ,需要配合G CSF的应用。 1例发生Ⅰ度腹泻和 1例发生Ⅰ度外周神经病变 ,未作特殊处理。结论 展开更多
关键词 胃癌 药物疗法 甲酰四氢叶酸钙 5-氟脲嘧啶 草酸铂
下载PDF
多西他赛、表柔比星联合环磷酰胺对局部晚期乳腺癌辅助化学治疗不同周期的疗效研究 被引量:19
19
作者 王志威 王杰 +4 位作者 魏敏 杨莉 邵玉国 籍敏 何奇 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2019年第12期1432-1436,共5页
目的·比较TEC方案(多西他赛+表柔比星+环磷酰胺)8周期和6周期对局部晚期乳腺癌术后辅助化学治疗(化疗)效果和不良反应的差异。方法·回顾性分析2008年4月-2015年4月于上海交通大学医学院附属国际和平妇幼保健院治疗的腋窝淋巴... 目的·比较TEC方案(多西他赛+表柔比星+环磷酰胺)8周期和6周期对局部晚期乳腺癌术后辅助化学治疗(化疗)效果和不良反应的差异。方法·回顾性分析2008年4月-2015年4月于上海交通大学医学院附属国际和平妇幼保健院治疗的腋窝淋巴结转移≥4枚的局部晚期乳腺癌患者66例。按照化疗周期的不同将患者分为2组,观察组(TEC×8组)(n=31)和对照组(TEC×6组)(n=35)。比较2组患者的3年总生存率、无病生存率的差异,以及2组患者发生骨髓抑制、发热及肝功能异常等不良反应的差异。组间比较采用χ~2检验,生存分析采用Kaplan-Meier法。结果·观察组的3年总生存率为93.5%,对照组为91.4%,2组比较差异无统计学意义(P=0.716)。观察组的3年无病生存率为87.1%,对照组为85.7%,2组比较差异无统计学意义(P=0.855)。观察组患者Ⅲ度或Ⅳ度骨髓抑制的发生率为90.3%,对照组为65.7%,2组比较差异有统计学意义(P=0.017)。观察组发热的发生率为16.1%,对照组为14.3%,2组比较差异无统计学意义(P=0.835)。观察组肝功能异常发生率为77.4%,对照组为85.7%,2组比较差异无统计学意义(P=0.383)。结论·TEC×8方案与TEC×6方案相比,未能提高局部晚期乳腺癌患者的总生存率和无病生存率,2组发热和肝功能异常的发生率也无差异,但TEC×8方案显著增加Ⅲ度或Ⅳ度骨髓抑制的发生率。 展开更多
关键词 多西他赛 表柔比星 环磷酰胺 乳腺癌 化学治疗 疗效 不良反应
下载PDF
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected nonresponders and relapsers after interferon alfa-2a monotherapy 被引量:19
20
作者 Perdita Wietzke-Braun Volker Meier +1 位作者 Felix Braun Giuliano Ramadori 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第2期222-227,共6页
AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chron... AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chronic hepatitis C virus-infected non-responders to interferon alfa2a monotherapy (a course of at least 3 months treatment) and 13 relapsers to interferon alfa 2a monotherapy (a dose of 3 to 6 million units three times per week for at least 20 weeks but not more than 18 months) were treated with the same dose of interferon alfa-2a used before (3 to 6 million units three times per week) and ribavirin (10 mg/ kg daily) for 6 months. In complete responders, interferon alfa-2a was administered for further 6 months at the same dose used before as monotherapy.RESULTS Seven (20.6%) of 34 non-responders stopped the combined therapy due to adverse events, including two patients with histological and clinical Child A cirrhosis. In 17/27 (63%)non-responders, the combined therapy was stopped after three months because of non-response. Ten of the 27 non-responders completed the 1;2-month treatment course. At a mean follow up of 28 months (16- 37 months)after the treatment, 4/10 (15%) previous non-responders still remained complete responders,All 13 previous relapsers completed the 12-month treatment course. At a mean follow up of 22months (9 - 36 months) after treatment, 6/13(46%) the previous relapsers were stillsustained complete responders.CONCLUSION Our treatment schedule of the combined therapy for 6 months of interferon alfa2a with a low dose of ribavirin (10 mg/kg/day)followed by 6 months of interferon alfa-2amonotherapy is able to induce a sustainedcomplete response rate in 15% of non-responders and 46% of relapsers with chronic hepatitis C virus-related liver diseases comparable to those obtained with the standarddoses of ribavirin 1000 - 1200 mg/day.Randomized prospective controlled trials using lower total amounts of ribavirin in combination with interferon should be performed. 展开更多
关键词 hepatitis C chronic/drug therapy INTERFERON alpha-2a/therapeutic use INTERFERON alpha-2a/administration & DOSAGE ribavirin/administration & DOSAGE ribavirin/therapeutic use
下载PDF
上一页 1 2 3 下一页 到第
使用帮助 返回顶部